Addyi Cannabis Interaction Profile: What Flibanserin Users Need to Know

What Flibanserin Is and How It Works

Flibanserin is a non-hormonal, centrally acting drug approved in August 2015 for acquired, generalized HSDD in premenopausal women. It acts as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, with additional dopamine D4 agonism. This combination shifts neurotransmitter balance in prefrontal reward circuits rather than acting on sex hormones directly. The FDA prescribing information notes that the precise mechanism underlying its effect on sexual desire is not fully understood. [1]

Why the Clearance Pathway Matters

Flibanserin is almost entirely metabolized by CYP3A4, with CYP2C19 contributing a smaller share. Co-administration with strong CYP3A4 inhibitors raises flibanserin area-under-the-curve (AUC) dramatically. The label reports that fluconazole, a moderate CYP3A4 inhibitor, increased flibanserin AUC by approximately 7-fold. [1] A strong inhibitor such as ketoconazole raised AUC by roughly 4.5-fold in dedicated pharmacokinetic studies cited in the label. [1]

Any substance that inhibits CYP3A4, even partially, may therefore increase flibanserin plasma concentrations, prolonging and intensifying sedation, dizziness, and blood pressure drops.

Who Is Prescribed Flibanserin

HSDD affects an estimated 8 to 10 percent of premenopausal women in population-based surveys, making it the most common female sexual dysfunction diagnosis. A 2016 review in the Journal of Sexual Medicine placed the prevalence of distressing low sexual desire at approximately 8.9 percent across age groups. [2] Because flibanserin targets a premenopausal population that overlaps substantially with working-age adults who may use cannabis recreationally or medically, the interaction question is clinically immediate.

The FDA Label and CNS Depressant Contraindication

The Addyi prescribing information carries a boxed warning about concurrent CNS depressant use and alcohol. The label states directly: "Concomitant use with alcohol or other CNS depressants is contraindicated." [1] The FDA required a Risk Evaluation and Mitigation Strategy (REMS) as a condition of approval, partly because of this interaction risk. The REMS program documentation outlines prescriber certification requirements and the mandatory patient-provider agreement. [3]

Why CNS Depressants Are Contraindicated

Phase III clinical trials submitted for Addyi approval showed that co-administration with a single dose of alcohol produced severe hypotension and syncope in a meaningful proportion of subjects. In the dedicated alcohol interaction study summarized in the label, approximately 4 of 23 subjects experienced hypotension or syncope. [1] The signal was strong enough that the FDA initially rejected the application twice before granting approval with the REMS. [3]

Cannabis acts as a CNS depressant through CB1 receptor agonism in the brain and spinal cord. A 2021 review in Pharmacological Reviews detailed how THC-mediated CB1 activation reduces neuronal excitability, slows psychomotor function, and lowers blood pressure through autonomic modulation. [4] These effects overlap directly with flibanserin's own sedative and hypotensive adverse effect profile.

The Syncope and Fall Risk in Practice

Flibanserin's bedtime dosing is not arbitrary. The label recommends 100 mg at bedtime specifically to reduce daytime sedation and the risk of falls. [1] Adding a CNS depressant to a patient who takes flibanserin at night and then rises to use the bathroom creates an environment where orthostatic hypotension, dizziness, and loss of consciousness are all plausible outcomes, not theoretical ones.

How Cannabis Inhibits CYP3A4 and Raises Flibanserin Exposure

THC and CYP3A4 Inhibition

Tetrahydrocannabinol (THC) is both a CYP3A4 substrate and an inhibitor. A 2019 study in Drug Metabolism and Disposition (PMID 30670485) demonstrated that THC inhibits CYP3A4 activity in human liver microsomes with a Ki in the low micromolar range. [5] At typical recreational plasma concentrations, the inhibitory effect may be clinically meaningful for drugs with a narrow therapeutic margin or steep concentration-effect curves. Flibanserin fits this description: even modest AUC increases substantially worsen hypotension and sedation.

CBD and CYP3A4 Inhibition

Cannabidiol (CBD) is a more potent CYP3A4 inhibitor than THC at comparable doses. A 2020 paper in Clinical Pharmacology and Therapeutics (PMID 31858579) showed that CBD inhibited CYP3A4-mediated metabolism of multiple co-administered drugs, raising AUC values by 1.3- to 2.5-fold depending on the substrate. [6] Patients using CBD-rich products, including over-the-counter hemp-derived CBD oils, may therefore face a larger interaction magnitude than those using THC-dominant cannabis.

Estimating the Magnitude of Interaction

No dedicated pharmacokinetic study has measured the flibanserin-cannabis interaction directly. This is a genuine evidence gap. Based on what is known about CYP3A4 inhibition by CBD (roughly moderate inhibitor potency) and the flibanserin-fluconazole interaction showing a 7-fold AUC increase with a moderate inhibitor, a clinically conservative estimate suggests that daily CBD use might raise flibanserin AUC by 2- to 5-fold. That range would be sufficient to push plasma concentrations into ranges associated with syncope risk in the fluconazole pharmacokinetic study. [1, 6]

Addyi and Alcohol: The Better-Studied Parallel

Because the alcohol interaction is the best-documented human pharmacodynamic interaction with flibanserin, it provides a useful reference frame for understanding the cannabis risk.

The Dedicated Alcohol Study

The interaction study in the label enrolled 25 subjects who received a single 100 mg dose of flibanserin with varying quantities of alcohol. Four subjects experienced hypotension or syncope. [1] Blood pressure drops were rapid, occurring within 30 to 60 minutes of co-ingestion. Recovery required placing subjects in the supine position; no subject required pharmacological intervention, but the severity of the events drove the contraindication language.

A 2015 analysis published in the Journal of Sexual Medicine reviewing the clinical trial program noted that even one standard drink was sufficient to trigger the interaction in some subjects. [7] The authors concluded that the interaction appeared to be pharmacodynamic rather than purely pharmacokinetic, meaning additive CNS and vascular depression rather than simply higher flibanserin levels.

Cannabis vs. Alcohol: Different Mechanisms, Overlapping Risks

Alcohol primarily enhances GABA-A receptor activity and inhibits NMDA receptors, adding sedation and vasodilation on top of flibanserin's profile. Cannabis adds CB1-mediated sedation and autonomic hypotension while also inhibiting CYP3A4, meaning the cannabis interaction has two distinct components (pharmacodynamic CNS/BP additive effects plus pharmacokinetic exposure increase) whereas alcohol's interaction is primarily pharmacodynamic. The combined-mechanism nature of the cannabis interaction may make it harder to predict in individual patients.

Flibanserin's Adverse Effect Profile Relevant to the Interaction

Understanding the baseline adverse effect profile of flibanserin clarifies why any CNS depressant amplifies risk substantially.

Sedation and Somnolence

In the pooled phase III trials (BEGONIA, VIOLET, and SNOWDROP), somnolence occurred in approximately 11 percent of flibanserin-treated subjects versus 2.8 percent of placebo subjects. A 2014 paper by Katz et al. In the Journal of Sexual Medicine (PMID 25145909) analyzed pooled data from these trials across more than 2,400 randomized subjects. [8] Dizziness occurred in approximately 11.4 percent of flibanserin subjects versus 2.2 percent on placebo.

Hypotension and Syncope

Hypotension was observed in 0.2 to 0.4 percent of subjects in the key trials at the labeled dose. Syncope was rare at baseline but increased sharply with CNS depressant co-administration. [1] These numbers appear small in isolation but translate to meaningful absolute risk when multiplied across a large population of users.

Nausea

Nausea affected roughly 10 percent of flibanserin users in the trials. [8] Cannabis-induced antiemetic effects might mask nausea that would otherwise alert a patient to excess flibanserin exposure, potentially delaying recognition of a more serious pharmacodynamic interaction.

What the Clinical Pharmacology Literature Adds

CYP3A4 Polymorphisms and Variable Risk

CYP3A4 activity varies by a factor of 10 to 100 between individuals due to genetic polymorphisms and environmental factors. A 2018 review in Drug Metabolism and Disposition (PMID 29437872) detailed how CYP3A4 5 and CYP3A4 22 alleles reduce enzyme activity by roughly 50 percent compared to wild-type. [9] A patient who is already a CYP3A4 poor metabolizer by genotype and then adds a CYP3A4 inhibitor (cannabis) faces a compounded exposure increase. Pre-treatment genotyping is not standard clinical practice for flibanserin, but it is worth considering in patients reporting unexpected sedation.

Drug Interaction Prediction Models

The FDA's guidance on drug interaction studies recommends that any substance producing greater than 2-fold inhibition of CYP3A4 in vitro be categorized as a moderate inhibitor and trigger contraindication or dose adjustment language for sensitive CYP3A4 substrates. The FDA Drug Interaction Guidance (2020) classifies flibanserin as a sensitive CYP3A4 substrate based on the large AUC changes seen with known inhibitors. [10] CBD's measured Ki values in human liver microsomes fall in the range consistent with moderate inhibition, reinforcing the clinical concern.

Route of Administration Matters

Smoked cannabis produces rapid THC and CBD plasma peaks within 10 to 30 minutes of inhalation, with plasma half-lives of roughly 30 minutes for THC. A 2020 pharmacokinetics review in Clinical Pharmacokinetics (PMID 31659635) summarized that peak THC concentrations after smoking a single cigarette containing 34 mg THC reached approximately 162 ng/mL, declining to below 5 ng/mL within 3 to 4 hours. [11] Oral or edible cannabis produces slower, more prolonged CBD and THC peaks, potentially sustaining CYP3A4 inhibition through the overnight period when flibanserin is active. Patients using edibles before bed may face a longer window of interaction.

Practical Guidance for Patients and Prescribers

Counseling Points Before Prescribing

Prescribers certifying under the Addyi REMS are required to counsel patients on the alcohol contraindication. [3] That conversation should be extended to include cannabis, particularly in states where recreational and medical cannabis are legal and widely used. Key points to convey include:

• Cannabis, including CBD-only products, inhibits CYP3A4 and may raise flibanserin blood levels.
• Concurrent use adds CNS depressant effects, increasing dizziness, sedation, and risk of falls or fainting.
• Edible and oral cannabis products may sustain the interaction for longer than smoked forms due to prolonged absorption.
• There is no established safe dose of cannabis while on flibanserin, given the absence of a dedicated interaction trial.

If a Patient Reports Concurrent Use

If a patient reports using cannabis and flibanserin together, the appropriate clinical steps include documenting the frequency, dose form, and THC/CBD content of the cannabis product. Blood pressure measurement in both supine and standing positions helps detect subclinical orthostatic hypotension. If the patient is unwilling or unable to stop cannabis, consider whether flibanserin is the appropriate therapy, or discuss a supervised washout period before restarting.

Monitoring Parameters

The Endocrine Society has not issued specific guidance on flibanserin co-prescribing, but the American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 615 notes that non-hormonal pharmacotherapy for HSDD should include structured follow-up at 4 and 8 weeks post-initiation to assess tolerability. [12] Blood pressure monitoring at these visits is a reasonable addition when CNS depressant use is suspected.

Special Populations and Considerations

Patients Using Medical Cannabis for Anxiety or Sleep

A subset of flibanserin candidates may use cannabis specifically to manage anxiety or insomnia, both of which can contribute to low sexual desire. A 2019 JAMA Internal Medicine study (PMID 30688979) found that 79 percent of medical cannabis users cited anxiety, pain, or sleep problems as their primary indications. [13] This creates a real clinical tension: the underlying conditions that cannabis is treating may also be driving HSDD, but the two drugs cannot safely be combined. Addressing sleep and anxiety through non-CYP3A4-inhibiting medications is an important consideration before starting flibanserin.

Patients on Hormonal Contraceptives

Many premenopausal women prescribed flibanserin also use hormonal contraceptives. Ethinyl estradiol-containing oral contraceptives are moderate CYP3A4 inhibitors and can raise flibanserin AUC by approximately 2-fold on their own. [1] Adding cannabis on top of an oral contraceptive and flibanserin may produce additive CYP3A4 inhibition, pushing flibanserin exposure higher still. This three-way interaction has not been studied.

Patients in States With Legal Cannabis

Prevalence of past-month cannabis use among adults aged 18 to 44 exceeded 20 percent in some state surveys following legalization, based on CDC BRFSS data for 2022. [14] The pool of flibanserin candidates who are concurrent cannabis users is therefore substantial, not hypothetical. Routine cannabis screening as part of the REMS prescribing conversation is warranted.

Gaps in the Evidence and Research Needs

No dedicated clinical pharmacokinetic trial has examined the flibanserin-cannabis interaction. This gap is partly structural: flibanserin is a federally approved Schedule IV drug, and cannabis remains Schedule I federally in the United States as of early 2025, complicating trial design and funding. The NIH National Institute on Drug Abuse maintains a research portfolio on cannabis pharmacokinetics but no registered trial (as of January 2025) specifically examines flibanserin co-administration. [15]

The absence of a trial does not mean the interaction is theoretical. It means the risk estimate rests on mechanism-based reasoning, in vitro inhibition data, and the parallel from stronger inhibitors tested in formal pharmacokinetic studies. Given flibanserin's known sensitivity to CYP3A4 inhibition and the documented CNS-depressant overlap, waiting for a dedicated trial before advising caution would not be clinically appropriate.